Cancer Drugs Have The Worst Phase III Track Record, BIO Study Shows
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Recent data on late-stage clinical success rates confirm that cancer drug development is a risky proposition for pharma/biotech companies, even before FDA gets tougher on accelerated approval requirements.
You may also be interested in...
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.